
WILEY

Intensifying Metastatic Hormone-Sensitive Prostate Cancer Treatment


The Role of Triplet Therapy



Visit https://hspc.knowledgehub.wiley.com/ for additional resources


Triplet therapy for mHSPC: the evidence

PEACE-1 trial¹¹



Visit https://hspc.knowledgehub.wiley.com/ for additional resources


Which factors determine the treatment intensification strategy to be used for each patient?¹⁴⁻¹⁶



Visit https://hspc.knowledgehub.wiley.com/ for additional resources

A new approach to treatment intensification¹⁶

Prescribe any of the following:



Considerations for treatment intensification in patients with mHSPC

Objectives:

• Delay progression • Prolong OS • Maintain quality of life

Though triplet therapy has been proved more effective, it may not necessarily be the new SOC

Healthcare providers should evaluate each patient and prescribe treatment intensification accordingly

References:

- 1. Klaassen, Z. (2022, May 10). Treatment intensification in metastatic hormone-sensitive prostate cancer. Prostate Cancer Foundation.
- Mandel, P., Hoeh, B., Wenzel, M., Preisser, F., Tian, Z., Tilki, D., ... & Chun, F.K.H. (2023). Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer patients: A systematic review and network meta-analysis. European Urology Focus, 9(1), 96–105.
- 3. Kyriakopoulos, C. E., Chen, Y. H., Carducci, M. A., Liu, G., Jarrard, D. F., Hahn, N. M., ... & Sweeney, C. J. (2018). Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. Journal of Clinical Oncology, 36(11), 1080.
- James, N.D., Sydes, M., Clarke, N.W., Mason, M.D., Dearnaley, D.P., Spears, M.R., ... & the STAMPEDE investigators. (2016). Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet, 387(10024), 1163–1177.
- Clarke, N. W., Ali, A., Ingleby, F. C., Hoyle, A., Amos, C. L., Attard, G., ... & James, N. D. (2019). Addition of docetaxel to hormonal therapy in low-and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Annals of Oncology, 30(12), 1992–2003.
- James, N. D., Clarke, N. W., Cook, A., Ali, A., Hoyle, A. P., Attard, G., ... & STAMPEDE Trials Collaborative Group. (2022). Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). International Journal of Cancer, 151(3), 422–434.
- Davis, I. D., Martin, A. J., Zielinski, R. R., Thomson, A., Tan, T. H., Sandhu, S., ... & Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). (2022). Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC). Journal of Clinical Oncology, 40(17), LBA5004–LBA5004.
- Chi, K. N., Chowdhury, S., Bjartell, A., Chung, B. H., Pereira de Santana Gomes, A. J., Given, R., ... & Agarwal, N. (2021). Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. *Journal of Clinical Oncology*, *39*(20), 2294–2303.
 Fizazi, K., Foulon, S., Carles, J., Roubaud, G., McDermott, R., Eléchon, A., & Bossi, A. (2022). Abiraterona plus predicione added to androgen deprivation therapy and docetaval in do novo metastatic.
- Fizazi, K., Foulon, S., Carles, J., Roubaud, G., McDermott, R., Fléchon, A., ... & Bossi, A. (2022). Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2× 2 factorial design. *The Lancet, 399*(10336), 1695–1707.
 Smith, M. R., Hussain, M., Saad, F., Fizazi, K., Sternberg, C. N., Crawford, E. D., ... & Tombal, B. (2022). Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. *New England Journal of*
- Medicine, 386(12), 1132–1142. 13. Bayer. (2016). A randomized, double-blind, placebo controlled phase III study of darolutamide (ODM-201) versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone sensitive prostate cancer. Available at: https://clinicaltrials.gov/ct2/show/NCT02799602.
- 14. Ali, A., Hoyle, A., Haran, Á. M., Brawley, C. D., Cook, A., Amos, C., ... & Clarke, N. W. (2021). Association of bone metastatic burden with survival benefit from prostate radiotherapy in patients with newly diagnosed metastatic prostate cancer: a secondary analysis of a randomized clinical trial. *JAMA Oncology*, 7(4), 555–563.
- Hussain, M., Tangen, C. M., Higano, C., Schelhammer, P. F., Faulkner, J., Crawford, E. D., ... & Raghavan, D. (2006). Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). Journal of Clinical Oncology, 24(24), 3984–3990
- 16. Morgans, A. K., & Beltran, H. (2022). Isn't androgen deprivation enough? Optimal treatment for newly diagnosed metastatic prostate cancer. *Journal of Clinical Oncology, 40(8),* 818–824. 17. Freedland, S. J., Agarwal, N., Ramaswamy, K., Sandin, R., Russell, D., Hong, A., ... & George, D. J. (2021). Real-world utilization of advanced therapies and racial disparity among patients with metastatic
- castration-sensitive prostate cancer (mCSPC): A Medicare database analysis. Journal of Clinical Oncology, 39(15), 5073. 18. Swami, U., Hong, A., El-Chaar, N. N., Nimke, D., Ramaswamy, K., Bell, E. J., ... & Agarwal, N. (2021). Real-world first-line (1L) treatment patterns in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in a US health insurance database. Cancers (Basel), 13(19), 4951.
- Heath, E. I., Dyson, G. E., Cackowski, F. C., Hafron, J., & Powell, I. (2022). Treatment intensification patterns and utilization in patients with metastatic castration-sensitive prostate cancer. *Clinical Genitourinary Cancer*, 20(6), 524–532.
- 20. Ryan, C. J., Ke, X., Lafeuille, M. H., Romdhani, H., Kinkead, F., Lefebvre, P., ... & Freedland, S. J. (2021). Management of patients with metastatic castration-sensitive prostate cancer in the real-world setting in the United States. *The Journal of Urology, 206*(6), 1420–1429.



//visit https://hspc.knowledgehub.wiley.com/ for additional resources

